DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Ribas A, Puzanov I, Dummer R. et al.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Lancet Oncol 2015;
16 (08) 908-918
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.